Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Advanced Heart Failure and Transplant
For patients acutely decompensated with ACC Stage C-D, NYHA 3-4, probable INTERMACS 4, how do you decide between MCS devices like CCM Barostim or potentially LVAD?
What are hemodynamic indices that would sway you between MCS or foregoing it?
Related Questions
Does the presence of diastolic dysfunction guide subsequent pharmacological, pacing and ablative therapies for atrial fibrillation?
In patients with moderate calcific mitral stenosis, possible HFpEF and dyspnea on exertion, how would you differentiate the etiology of the symptoms?
What are your preferred echocardiographic parameters and goals for weaning RVAD support?
In patients with resolved LV thrombus post-MI after 3-6 months of anticoagulation, would you consider surveillance imaging for thrombus recurrence if there is persistent apical akinesis?
How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?
Do you recommend avoiding ESAs in ESKD patients with heart failure who require a left ventricular assist device?
With the FDA recently approving acoramidis for ATTR cardiac amyloidosis, how should we decide on optimal drug therapy and options for our patients?
Can mavacamten be considered for patients with HCM and ongoing dyspnea in setting of an elevated LVEDP but without significant LV outflow obstruction on imaging?
How long do you wait before starting a non-selective beta blocker in patients with newly reduced LVEF and recent cocaine use?
What are standard selection criteria for patients who are eligible for heart transplantation?